ICR-CTSU
@icr-ctsu.bsky.social
410 followers 90 following 220 posts
Clinical Trials and Statistics Unit @icr.ac.uk‬ Translating cutting-edge science into quality clinical trials to transform cancer care. www.icr.ac.uk/ctsu
Posts Media Videos Starter Packs
icr-ctsu.bsky.social
Results showed that, for patients with head and neck cancer, there was no evidence of a difference in rates of key toxicities between standard intensity-modulated radiotherapy (IMRT) and proton beam therapy (PBT).
icr-ctsu.bsky.social
Results from the TORPEdO trial were presented at the American Society of Radiation Oncology (ASTRO) Annual Meeting last week.
icr.ac.uk
🚨 Big news from the TORPEdO trial

IMRT is just as effective as proton beam therapy for most head and neck cancer patients.

That means more people can access the best treatment locally—without needing specialist centres.

Learn more here ⬇️
www.icr.ac.uk/about-us/icr...
icr-ctsu.bsky.social
Ragu Ratnakumaran will be presenting 'Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated #radiotherapy (MHRT)' on Tuesday 20th September at 02:40pm PT in Room 22/23. #ProstateCancer
icr-ctsu.bsky.social
Dr David Thomson will be presenting 'Primary Results for the Phase III Trial of Toxicity Reduction using Proton Beam Therapy for #OropharyngealCancer (TORPEdO; CRUK/18/010)' in the plenary session on Monday 29th September at 1:48pm PT in the San Francisco Ballroom.
icr-ctsu.bsky.social
We are excited to be attending the 67th annual #ASTRO meeting in San Francisco where the TORPEdO primary results and the two-year toxicity outcomes from PACE-C will be presented. 🧪
Reposted by ICR-CTSU
icr.ac.uk
Today is #WorldCancerResearchDay 🌎 👩‍🔬 👨‍🔬

We're incredibly proud to have a community that is driving innovation, making ground-breaking discoveries, and transforming the future of cancer research.

Thank you to everyone who is helping us move closer to defeating cancer.
icr-ctsu.bsky.social
The results confirmed the impact of breast cancer diagnoses on people’s lives, even in a high-income country with a national health service.

The research was conducted as part of Szeyi Ng's PhD project, overseen by Prof Charlotte Coles, Prof Judith Bliss and Lucy Kilburn.
icr-ctsu.bsky.social
470 people with primary breast cancer and 136 with metastatic breast cancer responded. 27% PBC and 35% MBC respondents had experienced financial problems and 47% MBC respondents reported trouble fulfilling caring responsibilities at the time of survey completion.
Reposted by ICR-CTSU
icr.ac.uk
Recruitment to cancer #ClinicalTrials is often highly selective, and some people face barriers to participation.

To prevent these issues from limiting our progress against the disease, we're working to bridge the gap between clinical trials and real-world practice ⬇️

www.icr.ac.uk/research-and...
icr-ctsu.bsky.social
COBRA is investigating an alternative treatment for early bladder cancer and is currently in setup. Find out more information about the trial here:

www.icr.ac.uk/research-and...
COBRA infographic: BCG has been used to treat early bladder cancer for over 40 years and is put inside the bladder to stimulate the immune system to attack cancer cells. BCG can cause side effects which stop people from having a full course of treatment. Gem-Doce, two chemotherapy drugs, has been used in the bladder to treat early bladder cancer in the USA. The COBRA study will include 520 people from the UK with early bladder cancer. It will investigate whether Gem-Doce works as well as BCG to prevent cancer returning, with fewer side effects.
icr-ctsu.bsky.social
We're at the @abcuk.bsky.social bladder cancer training event today, to share information about our new trial COBRA.
A photo of the hall where the event is taking place, showing the welcome slide: Understanding Bladder Cancer and the latest developments COBRA trial flyers
icr-ctsu.bsky.social
Thank you to all the participants in FAST-Forward Boost which recruited its 100th patient last week.

The trial is investigating whether #Radiotherapy to treat #BreastCancer can be given in fewer treatment visits. You can learn more about the trial here: www.icr.ac.uk/ff-boost
Clinical trials detail
www.icr.ac.uk
icr-ctsu.bsky.social
Congratulations to @christinayap.bsky.social for being awarded a Cross-Sector Experience Award from @acmedsci.bsky.social to support her work on early phase and adaptive trials methodology, and the integration of patient-reported outcomes.
acmedsci.bsky.social
We're proud to announce Academy funding for 13 cross-sector partnerships 🤝

Our Cross-Sector Experience Awards supports awardees to work for up to a year in a different sector, sparking collaboration and transformative ideas 🚀

👉 Learn more: bit.ly/3HsZvgD
Eight profile images of the Academy's Cross Sector Experience Award recipients on a navy blue background
Reposted by ICR-CTSU
icr.ac.uk
We were joined this afternoon by MPs @luketaylorld.bsky.social, @bobbywdean.bsky.social and @paulkohlersw19.bsky.social 👋

Luke, Bobby and Paul met with Dr @maggiecheang.bsky.social to discuss her role at the ICR and the impact of her interdisciplinary research in the @icr-ctsu.bsky.social
icr-ctsu.bsky.social
Emily was also awarded an ESMO Merit travel grant for her work to support her attendance the conference. Congratulations Emily!
icr-ctsu.bsky.social
On Friday, PhD student Emily Alger @mle-alger.bsky.social will present her work “International consensus-driven recommendations for patient-reported outcome research objectives in early phase dose-finding oncology clinical trials: OPTIMISE-ROR” at the ESMO TAT Asia Congress. 🧪
icr-ctsu.bsky.social
We are looking at whether we get similar response rates in both groups and whether there is any difference in the answers people give. We will also see whether any groups of people prefer to complete questions either electronically or on paper.

Results should be available later this year.
icr-ctsu.bsky.social
Working closely with people with experience of cancer helps us make sure that our research asks important questions and will work for people joining our trials.

The SPRUCE study investigates using online surveys to collect information from participants, rather than paper questionnaires.
Reposted by ICR-CTSU